509 related articles for article (PubMed ID: 26408803)
1. Pathway-based approaches to the treatment of inflammatory bowel disease.
Bamias G; Pizarro TT; Cominelli F
Transl Res; 2016 Jan; 167(1):104-15. PubMed ID: 26408803
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
3. Experimental immunomodulatory therapy of inflammatory bowel disease.
Schreiber S
Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
[TBL] [Abstract][Full Text] [Related]
4. Contentious host-microbiota relationship in inflammatory bowel disease--can foes become friends again?
Satokari R
Scand J Gastroenterol; 2015 Jan; 50(1):34-42. PubMed ID: 25523554
[TBL] [Abstract][Full Text] [Related]
5. Current, experimental, and future treatments in inflammatory bowel disease: a clinical review.
Hvas CL; Bendix M; Dige A; Dahlerup JF; Agnholt J
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):446-460. PubMed ID: 29745777
[TBL] [Abstract][Full Text] [Related]
6. Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.
Vitale S; Strisciuglio C; Pisapia L; Miele E; Barba P; Vitale A; Cenni S; Bassi V; Maglio M; Del Pozzo G; Troncone R; Staiano A; Gianfrani C
PLoS One; 2017; 12(8):e0182313. PubMed ID: 28797042
[TBL] [Abstract][Full Text] [Related]
7. News from the "5th International Meeting on Inflammatory Bowel Diseases" CAPRI 2010.
Latella G; Fiocchi C; Caprili R
J Crohns Colitis; 2010 Dec; 4(6):690-702. PubMed ID: 21122584
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Flamant M; Rigaill J; Paul S; Roblin X
Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut.
Michielan A; D'Incà R
Mediators Inflamm; 2015; 2015():628157. PubMed ID: 26582965
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets for inflammatory bowel disease.
Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut.
Garcia-Carbonell R; Yao SJ; Das S; Guma M
Front Immunol; 2019; 10():1094. PubMed ID: 31164887
[TBL] [Abstract][Full Text] [Related]
13. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease.
Uhlig HH
Gut; 2013 Dec; 62(12):1795-805. PubMed ID: 24203055
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets.
Yadav V; Varum F; Bravo R; Furrer E; Bojic D; Basit AW
Transl Res; 2016 Oct; 176():38-68. PubMed ID: 27220087
[TBL] [Abstract][Full Text] [Related]
15. Biologic targeting in the treatment of inflammatory bowel diseases.
Bosani M; Ardizzone S; Porro GB
Biologics; 2009; 3():77-97. PubMed ID: 19707398
[TBL] [Abstract][Full Text] [Related]
16. Immune dysfunction in inflammatory bowel disease.
Neuman MG
Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
[TBL] [Abstract][Full Text] [Related]
17. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease.
Zhou G; Yu L; Yang W; Wu W; Fang L; Liu Z
Mediators Inflamm; 2016; 2016():2543070. PubMed ID: 27721573
[No Abstract] [Full Text] [Related]
18. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease.
Wang ZK; Yang YS; Chen Y; Yuan J; Sun G; Peng LH
World J Gastroenterol; 2014 Oct; 20(40):14805-20. PubMed ID: 25356041
[TBL] [Abstract][Full Text] [Related]
19. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy.
Merga Y; Campbell BJ; Rhodes JM
Dig Dis; 2014; 32(4):475-83. PubMed ID: 24969297
[TBL] [Abstract][Full Text] [Related]
20. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
Marafini I; Troncone E; Salvatori S; Monteleone G
Pharmacol Res; 2020 May; 155():104757. PubMed ID: 32194176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
